RA Capital Management Discloses Passive Stake in Edgewise Therapeutics

TL;DR

**RA Capital Management just revealed a significant, passive stake in Edgewise Therapeutics.**

AI Summary

RA Capital Management, L.P., a Delaware-based investment firm, filed an SC 13G on January 29, 2024, indicating its beneficial ownership of Edgewise Therapeutics, Inc. (EWGS) common stock as of January 19, 2024. This filing signals that RA Capital Management, along with its group members Peter Kolchinsky and RA Capital Healthcare Fund, L.P., holds a significant, though passive, stake in Edgewise Therapeutics. For investors, this matters because a prominent healthcare fund's involvement can be seen as a vote of confidence in Edgewise's future prospects and drug pipeline.

Why It Matters

This filing reveals a major institutional investor's position in Edgewise Therapeutics, potentially signaling market confidence and attracting further investor interest.

Risk Assessment

Risk Level: low — This filing indicates a passive investment by a large fund, which generally reduces immediate risk for existing shareholders.

Analyst Insight

A smart investor would research Edgewise Therapeutics' pipeline and financials, considering that a reputable healthcare fund like RA Capital has taken a position, which could signal underlying value or future growth potential.

Key Players & Entities

• RA Capital Management, L.P. (company) — reporting person and investment firm
• Edgewise Therapeutics, Inc. (company) — subject company (issuer)
• Peter Kolchinsky (person) — group member of RA Capital
• RA Capital Healthcare Fund, L.P. (company) — group member of RA Capital
• Delaware (company) — state of incorporation for RA Capital Management, L.P. and Edgewise Therapeutics, Inc.
• January 19, 2024 (date) — date of event requiring the filing
• January 29, 2024 (date) — filing date

Forward-Looking Statements

• Edgewise Therapeutics may see increased analyst coverage due to RA Capital's disclosed stake. (Edgewise Therapeutics, Inc.) — medium confidence, target: Q2 2024
• RA Capital Management will maintain a passive investment stance in Edgewise Therapeutics for the foreseeable future. (RA Capital Management, L.P.) — high confidence, target: Q4 2024

FAQ

Key Financial Figures

• $0.0001 — INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of

Filing Documents

• tm244273d1_sc13g.htm (SC 13G) — 89KB
• 0001104659-24-007744.txt ( ) — 91KB

(a). Name of Issuer

Item 1(a). Name of Issuer : Edgewise Therapeutics, Inc. (the "Issuer")

(b). Address of Issuer's Principal Executive Offices

Item 1(b). Address of Issuer's Principal Executive Offices : 1715 38 th St. Boulder, CO 80301

(a). Names of Persons Filing

Item 2(a). Names of Persons Filing : The names of the persons filing this report (collectively, the "Reporting Persons") are: RA Capital Management, L.P. ("RA Capital") Peter Kolchinsky Rajeev Shah RA Capital Healthcare Fund, L.P. (the "Fund")

(b). Address of Principal Business Office or, if None, Residence

Item 2(b). Address of Principal Business Office or, if None, Residence : The address of the principal business office of each of the Reporting Persons is: c/o RA Capital Management, L.P., 200 Berkeley Street, 18 th Floor, Boston MA 02116

(c). Citizenship

Item 2(c). Citizenship : RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.

(d). Title of Class of Securities

Item 2(d). Title of Class of Securities : Common Stock, $0.0001 par value per share ("Common Stock")

(e). CUSIP Number

Item 2(e). CUSIP Number : 28036F105

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b)

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable.

Ownership

Item 4. Ownership . The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The beneficial ownership percentages reported are based on 92,990,652 outstanding Common Stock shares, as confirmed directly to the Reporting Persons by the Issuer on January 24, 2024. The Fund directly holds 8,909,091 shares of Common Stock. RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund's portfolio, including the shares of the Issuer's Common Stock reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days' notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class . If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨ .

Ownership of More than Five Percent on Behalf of Another Person

Item 6. Ownership of More than Five Percent on Behalf of Another Person . Not applicable.

Identification and Classification of the Subsidiary Which Acquired the Security

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person . Not applicable.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group . Not applicable.

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group . Not applicable.

Certification

Item 10. Certification . By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Exhibit List Exhibit 1: Joint Filing Agreement SIGNATURE After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: January 29, 2024 RA CAPITAL MANAGEMENT, L.P. By: /s/ Peter Kolchinsky Name: Peter Kolchinsky Title: Authorized Signatory PETER KOLCHINSKY /s/ Peter Kolchinsky RAJEEV SHAH /s/ Ra jeev Shah RA CAPITAL HEALTHCARE FUND, L.P. By: RA Capital Healthcare Fund GP, LLC Its: General Partner By: /s/ Peter Kolchinsky Name: Peter Kolchinsky Title: Manager EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of January 29, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the "Filers"). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Common Stock, $0.0001 par value per share of Edgewise Therapeutics, Inc. beneficially owned by them from time to time. Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to suc

View Full Filing

View this SC 13G filing on SEC EDGAR